V Tammaro1, A Vernillo2, Xh Dumani2, I Florio2, L Pelosio3, A Jamshidi3, R Romagnuolo2, A Calogero2, N Carlomagno2, M Santangeloa3, A Renda3. 1. Interdepartmental Kidney Transplantation Center, University Federico II of Naples, Italy. Electronic address: vincenzo.tammaro@unina.it. 2. Department of Surgical Sciences and Nephrology, University Federico II, Naples, Italy. 3. Interdepartmental Kidney Transplantation Center, University Federico II of Naples, Italy.
Abstract
BACKGROUND: Fluid effusion (blood, lymph, or urine) in kidney transplantation may give rise to several complications, directly, such as hematoma, seroma, lymphocele, and/or urinoma, or consequently, such as increased infection risk, longer hospital stay, graft compression--with or without functional impairment--and necessity of further hospitalizations. The aim of this study was to evaluate effectiveness of hemostatic biomaterials in prevention of fluid effusions, especially lymphocele in kidney transplant patients. METHODS: We selected 40 patients who underwent kidney transplantation from 2009 to 2012 in which we used hemostatic biomaterials, and compared their results with those of other transplant patients from our center in which we did not used these biomaterials. Evaluated parameters were: fluid effusion, graft function, quality and quantity of drainage, blood count, and operative time. RESULTS: There was no difference in operative time. The incidence of complications on which biomaterials can have a role decreased; particularly, we observed a reduction from 24.21% to 7.5% of fluid effusions (lymphocele). There was no evidence of complications due to biomaterials. CONCLUSIONS: Hemostasis is important in surgery, and in kidney transplantations lymphostasis also has a significant role. In addition to the traditional hemostatic methods, recently some biomaterials, with the purpose of providing atraumatic hemostasis, were added. In our experience they are easy to use, and their use has proved to be effective for both hemostasis and lymphostasis with consequent reduction of fluid effusions.
BACKGROUND: Fluid effusion (blood, lymph, or urine) in kidney transplantation may give rise to several complications, directly, such as hematoma, seroma, lymphocele, and/or urinoma, or consequently, such as increased infection risk, longer hospital stay, graft compression--with or without functional impairment--and necessity of further hospitalizations. The aim of this study was to evaluate effectiveness of hemostatic biomaterials in prevention of fluid effusions, especially lymphocele in kidney transplant patients. METHODS: We selected 40 patients who underwent kidney transplantation from 2009 to 2012 in which we used hemostatic biomaterials, and compared their results with those of other transplant patients from our center in which we did not used these biomaterials. Evaluated parameters were: fluid effusion, graft function, quality and quantity of drainage, blood count, and operative time. RESULTS: There was no difference in operative time. The incidence of complications on which biomaterials can have a role decreased; particularly, we observed a reduction from 24.21% to 7.5% of fluid effusions (lymphocele). There was no evidence of complications due to biomaterials. CONCLUSIONS: Hemostasis is important in surgery, and in kidney transplantations lymphostasis also has a significant role. In addition to the traditional hemostatic methods, recently some biomaterials, with the purpose of providing atraumatic hemostasis, were added. In our experience they are easy to use, and their use has proved to be effective for both hemostasis and lymphostasis with consequent reduction of fluid effusions.
Authors: Mahyar Mohammadifard; Ghodratollah Naseh; Rozita Khatamian Oskooi; Gholamreza Sharifzadeh; Samira Eshraghi Journal: J Family Med Prim Care Date: 2019-05
Authors: Mohammad Golriz; Mohammadsadegh Sabagh; Golnaz Emami; Sara Mohammadi; Ali Ramouz; Elias Khajeh; Omid Ghamarnejad; Christian Morath; Markus Mieth; Yakup Kulu; Martin Zeier; Arianeb Mehrabi Journal: J Clin Med Date: 2021-11-30 Impact factor: 4.241
Authors: Mohammad Golriz; Mohammadsadegh Sabagh; Sara Mohammadi; Omid Ghamarnejad; Elias Khajeh; Markus Mieth; Mohammed Al-Saeedi; Markus K Diener; André L Mihaljevic; Christian Morath; Martin Zeier; Yakup Kulu; Arianeb Mehrabi Journal: BMJ Open Date: 2020-10-13 Impact factor: 2.692